Tumor size, axillary lymph node status and steroid receptor expression in breast cancer:: prognostic relevance 5 years after surgery

被引:30
作者
Gebauer, G
Fehm, T
Lang, N
Jäger, W
机构
[1] Univ Erlangen Nurnberg, Dept Obstet & Gynecol, D-91054 Erlangen, Germany
[2] Sidney Kimmel Canc Ctr, San Diego, CA USA
[3] Univ Texas, SW Med Sch, Ctr Canc Immunobiol, Dallas, TX 75230 USA
关键词
breast cancer; lymph node status; prognosis; steroid receptors; tumor size;
D O I
10.1023/A:1019601928290
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor size, axillary lymph node status and expression of steroid receptors are well-established prognostic factors in breast cancer. However, it is not clear if these prognostic factors are time-dependent variables and lose their significance after several years of disease-free survival. To analyse how long these factors keep their prognostic relevance survival of 1162 breast cancer patients was analysed retrospectively. The post-operative follow-up period was split into consecutive 2-year intervals and each interval was analysed for rate of recurrence and rate of tumor depending deaths. Furthermore, a multivariate analysis was performed for the total follow-up time and for the follow-up period starting 5 years after surgery. Multivariate analysis revealed tumor size, axillary lymph node status and estrogen receptor status as independent prognostic parameters. Analysing separately the rate of recurrences and tumor-related deaths during consecutive 2-year intervals, only the tumor size was a constant prognostic parameter, whereas prognostic relevance of lymph node status decreased. Estrogen receptor status associated with favourable prognosis during the first years after surgery changed to an unfavourable prognostic factor 4 years after surgery. To summarize, prognostic factors obtained at the time of surgery can lose their significance with increasing disease-free survival.
引用
收藏
页码:167 / 173
页数:7
相关论文
共 20 条
[1]  
ABE O, 1992, LANCET, V339, P71
[2]   Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. [J].
Braun, S ;
Pantel, K ;
Muller, P ;
Janni, W ;
Hepp, F ;
Kentenich, CRM ;
Gastroph, S ;
Wischnik, A ;
Dimpfl, T ;
Kindermann, G ;
Riethmuller, G ;
Schlimok, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (08) :525-533
[3]   Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer [J].
Budman, DR ;
Berry, DA ;
Cirrincione, CT ;
Henderson, IC ;
Wood, WC ;
Weiss, RB ;
Ferree, CR ;
Muss, HB ;
Green, MR ;
Norton, L ;
Frei, E .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (16) :1205-1211
[4]   Prognostic and predictive factors in breast cancer [J].
Bundred, NJ .
CANCER TREATMENT REVIEWS, 2001, 27 (03) :137-142
[5]  
CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO
[6]  
2-H
[7]   Clinical utility of serial serum c-erbB-2 determinations in the follow-up of breast cancer patients [J].
Fehm, T ;
Gebauer, G ;
Jäger, W .
BREAST CANCER RESEARCH AND TREATMENT, 2002, 75 (02) :97-106
[8]   Effect of preoperative chemotherapy on the outcome of women with operable breast cancer [J].
Fisher, B ;
Bryant, J ;
Wolmark, N ;
Mamounas, E ;
Brown, A ;
Fisher, ER ;
Wickerham, DL ;
Begovic, M ;
DeCillis, A ;
Robidoux, A ;
Margolese, RG ;
Cruz, AB ;
Hoehn, JL ;
Lees, AW ;
Dimitrov, NV ;
Bear, HD .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2672-2685
[9]   RELATIVE WORTH OF ESTROGEN OR PROGESTERONE-RECEPTOR AND PATHOLOGIC CHARACTERISTICS OF DIFFERENTIATION AS INDICATORS OF PROGNOSIS IN NODE NEGATIVE BREAST-CANCER PATIENTS - FINDINGS FROM NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT PROTOCOL B-06 [J].
FISHER, B ;
REDMOND, C ;
FISHER, ER ;
CAPLAN, R .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (07) :1076-1087
[10]   Epithelial cells in bone marrow of breast cancer patients at time of primary surgery:: Clinical outcome during long-term follow-up [J].
Gebauer, G ;
Fehm, T ;
Merkle, E ;
Beck, EP ;
Lang, N ;
Jäger, W .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3669-3674